Toll-like receptor 4 (TLR4)

Overview

toll-like receptor 4 (TLR4) is a pattern recognition receptor belonging to the toll-like receptor (TLR) family, encoded by the TLR4 gene. It is a transmembrane glycoprotein constitutively expressed on the surface of innate immune cells — including monocytes, macrophages, dendritic cells, neutrophils, and microglia — as well as on a variety of non-immune cell types such as hepatic stellate cells and neurons. TLR4 is best characterized as the primary sensor for lipopolysaccharide (LPS), a structural component of gram-negative bacterial cell walls, but it also recognizes endogenous danger signals (damage-associated molecular patterns, or DAMPs) such as high-mobility group box 1 protein (high mobility group box 1 (HMGB1)) and lumican. Upon ligand binding, TLR4 recruits the adapter protein myeloid differentiation primary response 88 (MyD88), initiating downstream signaling cascades that culminate in the activation of nuclear factor kappa B (NF-κB) and the production of proinflammatory cytokines including interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).

Beyond its canonical role in host defense against bacterial infection, TLR4 is increasingly recognized as a central mediator of sterile inflammation across a broad spectrum of pathological conditions. Its activation drives tissue-damaging neuroinflammation in neurodegenerative and neuropathic pain states, promotes fibrosis, facilitates tumor progression and metastasis, and modulates immunophenotypic changes in circulating leukocytes exposed to environmental or pharmacological stressors. This dual role — protective in acute infection yet injurious in chronic or dysregulated contexts — makes TLR4 a high-priority research target for therapeutic intervention in inflammation-driven diseases, ranging from metabolic dysfunction–associated steatotic liver disease (MAFLD/NAFLD) to Parkinson's disease and cancer.

Recent Publications Focus

Recent studies have continued to position TLR4 as a central inflammatory target across metabolic, neurological, pulmonary, and oncologic disease models. In obese polycystic ovary syndrome, hypothalamic TLR4/IKKbeta signaling was implicated in the link between insulin resistance and impaired endometrial receptivity; central administration of the TLR4 inhibitor TAK242 was reported to be more effective than systemic delivery, improving insulin sensitivity, limiting weight gain, and restoring endometrial receptivity in rats 42466701Jul. In acute kidney injury caused by ischemia-reperfusion, adipose-derived mesenchymal stem cells reduced serum creatinine and blood urea nitrogen, improved renal injury and oxidative stress, and were associated with lower TLR4 protein levels, reduced inflammatory mediators, and decreased endoplasmic reticulum stress proteins 42435285Jul. In acute lung injury, an ethyl acetate fraction from Madeng'ai attenuated pulmonary pathology, edema, and inflammatory responses, with validation suggesting inhibition of TLR4-mediated inflammatory signaling alongside modulation of the PI3K/AKT pathway 41941987Apr.

Several publications focused on TLR4-linked neuroinflammation and cell death pathways. In desert dry-heat-induced exertional heat stroke, nanocurcumin reduced neuronal injury, lowered inflammatory cytokines, improved neuroendocrine and biochemical injury markers, and dose-dependently inhibited TLR4, MyD88, and NF-κB protein expression in brain tissue 42396648Jul. In ischemic stroke, astaxanthin improved neurological deficits, reduced edema, infarct volume, and apoptosis, and its protective effects were reversed by the TLR4 agonist RS 09, supporting inhibition of the TLR4 pathway as a key mechanism 42050264Apr. In Parkinson’s disease mice, Astragaloside IV directly bound TLR4, suppressed TLR4/NF-κB signaling in microglia, improved motor and anxiety-like behaviors, and lost efficacy in TLR4-deficient mice 41846059Mar. In trigeminal neuropathic pain, Liquiritin was proposed to act through TLR4/MyD88-dependent modulation of microglial M1-like polarization 41880679Mar. In Alzheimer’s disease-related computational work, TLR4 emerged among key overlapping immune-inflammatory targets associated with gut microbiota-derived metabolites, alongside IL6, NFKB1, IL1B, and Peroxisome proliferator-activated receptor gamma (PPARγ) 42406869Jul.

Other studies examined TLR4 in cancer, autoimmune disease, and inflammatory tissue remodeling. Cauloside A was reported to bind TLR4 and trigger JNK/caspase-3/GSDME-dependent pyroptosis in non-small cell lung cancer cells, suppressing tumor growth in mice and activating a TLR4-JNK-caspase-3-GSDME axis in tumor tissue 42085840May. In lung adenocarcinoma, TLR4 was identified as one of six core PANoptosis-related genes, enriched in M2 macrophages, and ginsenosides were reported to inhibit the TLR4/NLRP3 survival signaling axis in vitro 41935997Apr. In Crohn’s disease, Xue-Jie-San reduced endothelial pyroptosis, restored barrier function, and blocked TLR4/MyD88/NF-κB signaling upstream of NLRP3 inflammasome activation; overexpression of TLR4 abolished the anti-pyroptotic effect 41936260Apr. In rheumatoid arthritis, phenylpropanoids from Dendropanax proteus were shown to reduce TLR4 protein expression in TNF-α-stimulated MH7A cells and were proposed to inhibit the TLR4-COX-2 signaling axis 41924844Apr. In liver fibrosis, a Lumican-TLR4 interaction was reported to accelerate hepatic fibrosis by activating hepatic stellate cells 42043860Apr, while in NAFLD, rutin was found to directly bind RUNX1, disrupt the RUNX1/TET2 complex, and alleviate disease through downstream TLR4/NF-κB inhibition 41997405Apr.

TLR4 also appeared in vaccine and immunomodulatory studies. BECC adjuvants were described as novel TLR4 ligands that enhanced recombinant hemagglutinin influenza vaccine immunogenicity, promoting strong humoral and cellular responses and durable immune memory 42218860May. An intranasal liposomal mucosal vaccine combining TLR4 and TLR7/8 ligands with Ovalbumin (OVA) provided broad protection in mice against multiple respiratory threats, including SARS-CoV-2 and Staphylococcus aureus, through persistent memory T cells and alveolar macrophage imprinting 41712698Feb. In microglial alarmin signaling research, proximity ligation assays confirmed interactions involving TLR4, ST2, and RAGE, and differentially charged dendrimers modulated IL-33 and high mobility group box 1 (HMGB1) receptor interactions in lipopolysaccharide-activated human microglia 42081615May.

What Changes, What Holds

1. TLR4 inhibition is emerging as a disease-modifying strategy in metabolic and inflammatory injury models
REINFORCES These studies extend the established proinflammatory role of TLR4 into additional metabolic, renal, and pulmonary settings, but they do not alter the core account that TLR4 drives inflammatory injury. The central-vs-systemic TAK242 comparison suggests route of delivery may matter for efficacy in hypothalamic TLR4 signaling, while the other findings support TLR4 as a therapeutic target in acute organ injury rather than redefining its biology 42466701Jul42435285Jul.

2. TLR4 remains a convergent node for neuroinflammation, but the new work broadens the disease contexts and upstream modulators
REINFORCES The neurobiology here is consistent with the baseline view that TLR4 promotes damaging inflammation in neurologic disease, and the added studies sharpen that picture by linking TLR4/MyD88/NF-κB signaling to heat stroke, stroke, Parkinsonian phenotypes, and neuropathic pain. The direct binding claim for Astragaloside IV strengthens target engagement, but the overall message is still extension of the known inflammatory role, not a change in mechanism 42396648Jul41846059Mar.

3. TLR4 is being implicated in additional inflammatory remodeling and cell-death programs across cancer, gut, liver, and autoimmune disease
REINFORCES These reports reinforce the baseline’s broad claim that TLR4 contributes to fibrosis, tumor progression, and chronic inflammatory pathology, while adding more specific downstream programs such as pyroptosis, PANoptosis-related signaling, and barrier injury. The Lumican-TLR4 fibrosis result is especially aligned with the established DAMP-sensing role, and the NAFLD and rheumatoid arthritis findings further support TLR4 as a downstream effector rather than revising its canonical function 42085840May42043860Apr.

4. TLR4 is also being repurposed as an adjuvant target and immune-engineering handle
NEW DIRECTION The vaccine studies cover no role in the Overview beyond innate sensing, so using TLR4 ligands to enhance immunogenicity and durable memory adds a new application rather than contradicting the baseline. The microglial receptor-interaction work likewise shifts attention toward how TLR4 participates in receptor complexes and alarmin signaling architecture, which is a methodological and mechanistic extension, not a replacement of the LPS/DAMP-centered account 42218860May41712698Feb.

Overview update candidates: central TLR4 inhibition as a potentially more effective route in hypothalamic metabolic signaling; TLR4 as an adjuvant target for vaccine immunogenicity; receptor-complex/alarmin interaction studies in microglia.